Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas S Griffith

Showing results (11-20 of 179) with videos related to

Pageof 18
Sort By:
Immunotherapy|January 5, 2010
Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladderTimothy P Kresowik, Thomas S Griffith
Cancer Chemotherapy and Pharmacology|June 18, 2003
The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosisThomas S Griffith, Troy J Kemp
The Journal of Pharmacology and Experimental Therapeutics|January 6, 2019
Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer VaccineHyunjoon Kim, Thomas S Griffith, Jayanth Panyam
Immunotherapy|March 27, 2020
Exploiting antibody biology for the treatment of cancerVidhi Khanna, Jayanth Panyam, Thomas S Griffith
Pharmacology & Therapeutics|September 8, 2015
Therapeutic applications of TRAIL receptor agonists in cancer and beyondGustavo P Amarante-Mendes, Thomas S Griffith
Journal of Andrology|February 24, 2009
The use of immunofluorescence in microdissection testicular sperm extractionJason R Greenhalgh, Thomas S Griffith, Moshe Wald
Frontiers in Immunology|February 9, 2023
Sepsis-induced changes in differentiation, maintenance, and function of memory CD8 T cell subsetsMohammad Heidarian, Thomas S Griffith, Vladimir P Badovinac
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2003
Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulationTroy J Kemp, Bennett D Elzey, Thomas S Griffith
Urologic Oncology|July 3, 2008
Role of neutrophils in BCG immunotherapy for bladder cancerMark P Simons, Michael A O'Donnell, Thomas S Griffith
Cancer Research|January 7, 2006
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cellsJames K Earel, Rebecca L VanOosten, Thomas S Griffith
Pageof 18

Showing results (11-20 of 179) with videos related to

Sort By:
Pageof 18
Immunotherapy|January 5, 2010
Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladderTimothy P Kresowik, Thomas S Griffith
Cancer Chemotherapy and Pharmacology|June 18, 2003
The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosisThomas S Griffith, Troy J Kemp
The Journal of Pharmacology and Experimental Therapeutics|January 6, 2019
Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer VaccineHyunjoon Kim, Thomas S Griffith, Jayanth Panyam
Immunotherapy|March 27, 2020
Exploiting antibody biology for the treatment of cancerVidhi Khanna, Jayanth Panyam, Thomas S Griffith
Pharmacology & Therapeutics|September 8, 2015
Therapeutic applications of TRAIL receptor agonists in cancer and beyondGustavo P Amarante-Mendes, Thomas S Griffith
Journal of Andrology|February 24, 2009
The use of immunofluorescence in microdissection testicular sperm extractionJason R Greenhalgh, Thomas S Griffith, Moshe Wald
Frontiers in Immunology|February 9, 2023
Sepsis-induced changes in differentiation, maintenance, and function of memory CD8 T cell subsetsMohammad Heidarian, Thomas S Griffith, Vladimir P Badovinac
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2003
Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulationTroy J Kemp, Bennett D Elzey, Thomas S Griffith
Urologic Oncology|July 3, 2008
Role of neutrophils in BCG immunotherapy for bladder cancerMark P Simons, Michael A O'Donnell, Thomas S Griffith
Cancer Research|January 7, 2006
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cellsJames K Earel, Rebecca L VanOosten, Thomas S Griffith
Pageof 18